Hikma launches Bleomycin for Injection, USP

Product

Hikma launches Bleomycin for Injection, USP

London, 18 July 2018 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces that Hikma Pharmaceuticals USA Inc., formerly known as West-Ward Pharmaceuticals, has launched Bleomycin for Injection, USP, 15U and 30U, the generic equivalent to Blenoxane®.

Hikma’s Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of certain types of Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, and Malignant Pleural Effusion.

According to IQVIA, US sales of Bleomycin for Injection, USP, 15U and 30U, were approximately $4 million in the 12 months ending May 2018.